These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36209558)

  • 1. Long-term methylphenidate exposure and 24-hours blood pressure and left ventricular mass in adolescents and young adults with attention deficit hyperactivity disorder.
    Buitelaar JK; van de Loo-Neus GHH; Hennissen L; Greven CU; Hoekstra PJ; Nagy P; Ramos-Quiroga A; Rosenthal E; Kabir S; Man KKC; Ic W; Coghill D;
    Eur Neuropsychopharmacol; 2022 Nov; 64():63-71. PubMed ID: 36209558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).
    McCarthy S; Neubert A; Man KKC; Banaschewski T; Buitelaar J; Carucci S; Coghill D; Danckaerts M; Falissard B; Garas P; Häge A; Hollis C; Inglis S; Kovshoff H; Liddle E; Mechler K; Nagy P; Rosenthal E; Schlack R; Sonuga-Barke E; Zuddas A; Wong ICK
    BMC Psychiatry; 2018 Oct; 18(1):327. PubMed ID: 30305167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
    Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
    J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuity in methylphenidate treatment of adults with attention-deficit/hyperactivity disorder.
    Olfson M; Marcus SC; Zhang HF; Wan GJ
    J Manag Care Pharm; 2007 Sep; 13(7):570-7. PubMed ID: 17874863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.
    Li L; Wang Y; Uppoor RS; Mehta MU; Farchione T; Mathis MV; Zhu H
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):245-262. PubMed ID: 28214989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Rösler M; Fischer R; Ammer R; Ose C; Retz W
    Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and individual severity of arterial blood pressure changes in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate hydrochloride: a prospective non-interventional study.
    Busold-Hagenbeck D; Elmenhorst J; Irtel von Brenndorff C; Hilgers R; Hulpke-Wette M
    Gen Psychiatr; 2020; 33(2):e100193. PubMed ID: 32420522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression.
    Liang EF; Lim SZ; Tam WW; Ho CS; Zhang MW; McIntyre RS; Ho RC
    Int J Environ Res Public Health; 2018 Aug; 15(8):. PubMed ID: 30127314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
    Man KKC; Häge A; Banaschewski T; Inglis SK; Buitelaar J; Carucci S; Danckaerts M; Dittmann RW; Falissard B; Garas P; Hollis C; Konrad K; Kovshoff H; Liddle E; McCarthy S; Neubert A; Nagy P; Rosenthal E; Sonuga-Barke EJS; Zuddas A; Wong ICK; Coghill D;
    Lancet Psychiatry; 2023 May; 10(5):323-333. PubMed ID: 36958362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
    Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
    JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
    Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
    Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
    Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R;
    World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.